113 related articles for article (PubMed ID: 17366548)
1. A fifteen-year cytogenetic remission following interferon treatment in a patient with an indolent ETV6-ABL positive myeloproliferative syndrome.
Mozziconacci MJ; Sainty D; Chabannon C
Am J Hematol; 2007 Jul; 82(7):688-9. PubMed ID: 17366548
[No Abstract] [Full Text] [Related]
2. Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors.
Nand R; Bryke C; Kroft SH; Divgi A; Bredeson C; Atallah E
Leuk Res; 2009 Aug; 33(8):1144-6. PubMed ID: 19394693
[TBL] [Abstract][Full Text] [Related]
3. Extramedullary T-lymphoid blast crisis of an ETV6/ABL1-positive myeloproliferative neoplasm with t(9;12)(q34;p13) and t(7;14)(p13;q11.2).
Yamamoto K; Yakushijin K; Nakamachi Y; Miyata Y; Sanada Y; Tanaka Y; Okamura A; Kawano S; Hayashi Y; Matsuoka H; Minami H
Ann Hematol; 2014 Aug; 93(8):1435-8. PubMed ID: 24318592
[No Abstract] [Full Text] [Related]
4. Myeloproliferative disorders carrying the t(8;9) (PCM1-JAK2) translocation.
Bousquet M; Brousset P
Hum Pathol; 2006 Apr; 37(4):500; author reply 500-2. PubMed ID: 16564930
[No Abstract] [Full Text] [Related]
5. Insertion (12;9)(p13;q34q34): a cryptic rearrangement involving ABL1/ETV6 fusion in a patient with Philadelphia-negative chronic myeloid leukemia.
Kelly JC; Shahbazi N; Scheerle J; Jahn J; Suchen S; Christacos NC; Mowrey PN; Witt MH; Hostetter A; Meloni-Ehrig AM
Cancer Genet Cytogenet; 2009 Jul; 192(1):36-9. PubMed ID: 19480935
[TBL] [Abstract][Full Text] [Related]
6. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation.
Murati A; Gelsi-Boyer V; Adélaïde J; Perot C; Talmant P; Giraudier S; Lodé L; Letessier A; Delaval B; Brunel V; Imbert M; Garand R; Xerri L; Birnbaum D; Mozziconacci MJ; Chaffanet M
Leukemia; 2005 Sep; 19(9):1692-6. PubMed ID: 16034466
[No Abstract] [Full Text] [Related]
7. A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease.
Curtis CE; Grand FH; Waghorn K; Sahoo TP; George J; Cross NC
Leukemia; 2007 Aug; 21(8):1839-41. PubMed ID: 17508004
[No Abstract] [Full Text] [Related]
8. Identification of a novel ETV6 truncated fusion gene in myeloproliferative neoplasm, unclassifiable with t(4;12)(q12;p13).
Zhang L; Wang M; Wang Z; Zeng Z; Wen L; Xu Y; Yao L; Cen J; Li H; Pan J; Sun A; Wu D; Chen S; Ma L; Yang X
Ann Hematol; 2020 Oct; 99(10):2445-2447. PubMed ID: 32734549
[No Abstract] [Full Text] [Related]
9. Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement.
Tiribelli M; Barraco D; Medeot M; Marin L; Ottaviani E; De Marchi F; Damiani D; Fanin R
Ann Hematol; 2015 Aug; 94(8):1423-4. PubMed ID: 25900790
[No Abstract] [Full Text] [Related]
10. Molecular cytogenetic findings in a four-way t(1;12;5;12)(p36;p13;q33;q24) underlying the ETV6-PDGFRB fusion gene in chronic myelomonocytic leukemia.
Crescenzi B; La Starza R; Nozzoli C; Ciolli S; Matteucci C; Romoli S; Rigacci L; Gorello P; Bosi A; Martelli MF; Marynen P; Mecucci C
Cancer Genet Cytogenet; 2007 Jul; 176(1):67-71. PubMed ID: 17574967
[TBL] [Abstract][Full Text] [Related]
11. Complete molecular remission after interferon alpha treatment in a case of 8p11 myeloproliferative syndrome.
Zhou L; Fu W; Yuan Z; Hou J
Leuk Res; 2010 Nov; 34(11):e306-7. PubMed ID: 20650528
[No Abstract] [Full Text] [Related]
12. Myeloid/lymphoid neoplasms with eosinophilia/ basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase inhibition.
Yao J; Xu L; Aypar U; Meyerson HJ; Londono D; Gao Q; Baik J; Dietz J; Benayed R; Sigler A; Yabe M; Dogan A; Arcila ME; Roshal M; Zhang Y; Mauro MJ; Xiao W
Haematologica; 2021 Feb; 106(2):614-618. PubMed ID: 32299902
[No Abstract] [Full Text] [Related]
13. ZBTB44-FLT3 fusion in a patient with a myeloproliferative neoplasm.
Zhou X; Yang C; Zou Z; Lang X; Chen P; Chen S; Wang K; Chen Y; Hao Y; Chen N; Ding J; Li Y; Shen Y; Xiao S
Br J Haematol; 2020 Oct; 191(2):297-301. PubMed ID: 32866288
[No Abstract] [Full Text] [Related]
14. Oncogenic signals as treatment targets in classic myeloproliferative neoplasms.
Tefferi A; Levine RL; Kantarjian H
Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):114-9. PubMed ID: 19147089
[TBL] [Abstract][Full Text] [Related]
15. ALK fusion genes in children with atypical myeloproliferative leukemia.
Röttgers S; Gombert M; Teigler-Schlegel A; Busch K; Gamerdinger U; Slany R; Harbott J; Borkhardt A
Leukemia; 2010 Jun; 24(6):1197-200. PubMed ID: 20428197
[No Abstract] [Full Text] [Related]
16. Chronic phase of ETV6-ABL1 positive CML responds to imatinib.
Kawamata N; Dashti A; Lu D; Miller B; Koeffler HP; Schreck R; Moore S; Ogawa S
Genes Chromosomes Cancer; 2008 Oct; 47(10):919-21. PubMed ID: 18615681
[No Abstract] [Full Text] [Related]
17. Broad molecular screening of an unclassifiable myeloproliferative disorder reveals an unexpected ETV6/ABL1 fusion transcript.
Meyer-Monard S; Mühlematter D; Streit A; Chase AJ; Gratwohl A; Cross NC; Jotterand M; Tichelli A
Leukemia; 2005 Jun; 19(6):1096-9. PubMed ID: 15789067
[No Abstract] [Full Text] [Related]
18. ETV6/GOT1 fusion in a case of t(10;12)(q24;p13)-positive myelodysplastic syndrome.
Struski S; Mauvieux L; Gervais C; Hélias C; Liu KL; Lessard M
Haematologica; 2008 Mar; 93(3):467-8. PubMed ID: 18310541
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment with imatinib mesylate in a case of chronic myeloproliferative disorder with a t(5;12)(q33;p13.1) without eosinophilia.
Nadal N; Flandrin P; Cornillon J; Delabesse E; Mauvieux L; Olaru D; Morel S; Campos L
Cancer Genet Cytogenet; 2006 Sep; 169(2):174-5. PubMed ID: 16938578
[No Abstract] [Full Text] [Related]
20. [Molecular bases of leukemia, MPD and MDS].
Kitamura T
Rinsho Ketsueki; 2009 Mar; 50(3):174-81. PubMed ID: 19352084
[No Abstract] [Full Text] [Related]
[Next] [New Search]
